BridgeBio Pharma Free Cash Flow 2018-2024 | BBIO
BridgeBio Pharma free cash flow from 2018 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| BridgeBio Pharma Annual Free Cash Flow |
| 2023 |
-529.03 |
| 2022 |
-424.32 |
| 2021 |
-511.18 |
| 2020 |
-407.23 |
| 2019 |
-256.23 |
| 2018 |
-138.82 |
| 2017 |
-40.95 |
| BridgeBio Pharma Quarterly Free Cash Flow |
| 2024-09-30 |
-326.29 |
| 2024-06-30 |
-145.58 |
| 2024-03-31 |
-220.23 |
| 2023-12-31 |
-529.03 |
| 2023-09-30 |
-403.77 |
| 2023-06-30 |
-258.12 |
| 2023-03-31 |
-144.33 |
| 2022-12-31 |
-424.32 |
| 2022-09-30 |
-330.27 |
| 2022-06-30 |
-194.35 |
| 2022-03-31 |
-161.49 |
| 2021-12-31 |
-511.18 |
| 2021-09-30 |
-374.75 |
| 2021-06-30 |
-246.73 |
| 2021-03-31 |
-152.73 |
| 2020-12-31 |
-407.23 |
| 2020-09-30 |
-308.68 |
| 2020-06-30 |
-176.45 |
| 2020-03-31 |
-88.40 |
| 2019-12-31 |
-256.23 |
| 2019-09-30 |
-178.28 |
| 2019-06-30 |
-127.90 |
| 2019-03-31 |
-59.57 |
| 2018-12-31 |
|
| 2018-09-30 |
-91.67 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.426B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
